CRISPR technology ownership decided – The Aquinas – The Aquinas
WIRED |
CRISPR technology ownership decided – The Aquinas
The Aquinas The CRISPR patent case that was being investigated since 2013 was finally decided on Wednesday, Feb. 15, 2017. The U.S. Patent and Trademark Office … Should Anyone Own the Most Powerful Gene Editing Technology Ever Invented?Gizmodo The Long-Shot Bid to Put Crispr in the Hands of the PeopleWIRED 3Q: US patent office’s ruling on CRISPRMIT News IAM (registration) (blog) –GenomeWeb –Forbes all 18 news articles » |
OncLive |
Dr. Drake on Promise of Immunotherapy Combinations in Genitourinary Cancers
OncLive Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the potential of combinations between immunotherapy … |
OncLive |
Dr. Drake on Promise of Immunotherapy Combinations in Genitourinary Cancers
OncLive Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the potential of combinations between immunotherapy … |
W Magazine |
Thanks to Stem Cell Therapy, Thinning Hair May Be a Thing of the Past
W Magazine Call me a creature of habit, or just plain boring, but I’ve been wearing my hair long, blonde, straight, and side-parted for more than 15 years. The only thing that’s really changed is how much of it I have left. Whether the result of bleach, blowouts … |
Immuno-Oncology News |
Phase 1 Trial of CAR T-Cell Drug for Pancreatic Cancer Doses First Patient
Immuno-Oncology News The Phase 1 trial assessing Bellicum Pharmaceuticals’ BPX-601, a CAR T-cell therapy against the prostate stem cell antigen (PSCA), in inoperable pancreatic cancer has dosed its first patient. The company says this is the first CAR T-cell therapy aimed … |
Gizmodo |
Should Anyone Really Control Who Gets to Use CRISPR?
Gizmodo Last week, the US Patent and Trademarks office handed down a decision in one of the most high-profile patent cases of the century. In a one sentence ruling, an appeals board granted the rights to the powerful gene editing technology CRISPR-Cas9 to the … The Long-Shot Bid to Put Crispr in the Hands of the People | WIREDWIRED 3Q: US patent office’s ruling on CRISPR | MIT NewsMIT News PTAB issues key decision over revolutionary CRISPR technology, but this tale is not over yetIAM (registration) (blog) GenomeWeb –Forbes –JD Supra (press release) all 14 news articles » |